NCT07190300ClinicalTrials.gov
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer
In brief
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer (mHSPC). Phase I aims to determine the recommended dose(s)…
Phase 1 / Phase 2181 participants sought31 sites14 countries
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07190300Open this record at ClinicalTrials.govSynced 5 days ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-09-24; recorded start 2026-01-13
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 31 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 181 participants (target), run at 31 sites, across 14 countries.
How this score is built
- Enrolment21/40
181 participants (target)
- Site count18/25
31 sites
- Country count12/15
14 countries
- Planned duration10/10
Planned over about 80 months
- Sponsor scale10/10
Novartis Pharmaceuticals has led 1,104 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer (mHSPC). Phase I aims to determine the recommended dose(s) for expansion (RDE) of tulmimetostat in combination with darolutamide or abiraterone. Phase II is designed to further evaluate the efficacy and safety of tulmimetostat in combination with darolutamide compared with darolutamide alone in participants with mHSPC.
Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Eligibility
| Sex | Male |
|---|---|
| Ages | 18 Years – No maximum |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 1 / Phase 2 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | QUADRUPLE (4) |
| Enrolment | 181 participants sought |
Sponsor and collaborators
- Novartis Pharmaceuticals Sponsor
Arms and interventions
- Phase I: Group A (part 1)EXPERIMENTAL
Tulmimetostat administered orally once daily (QD) at escalating dose levels in combination with darolutamide 600 mg orally twice daily (BID). Participants will continue androgen deprivation therapy (ADT) throughout the study.
- Phase I: Group B (part 2)EXPERIMENTAL
Tulmimetostat administered orally once daily (QD) at escalating dose levels in combination with abiraterone 1000 mg orally once daily (QD). Participants will continue androgen deprivation therapy (ADT). Abiraterone will be administered with prednisone/prednisolone according to local prescribing information.
- Phase II: Arm 1EXPERIMENTAL
Tulmimetostat Dose 1 orally once daily (QD) in combination with darolutamide 600 mg orally twice daily (BID). Participants will continue androgen deprivation therapy (ADT).
- Phase II: Arm 2 (Optional)EXPERIMENTAL
Tulmimetostat Dose 2 orally once daily (QD) in combination with darolutamide 600 mg orally twice daily (BID). Participants will continue androgen deprivation therapy (ADT). This arm will be included if two recommended dose(s) for expansion are selected from Phase I.
- Phase II: Arm 3 (Control)ACTIVE_COMPARATOR
Darolutamide 600 mg orally twice daily (BID). Participants will continue androgen deprivation therapy (ADT).
Interventions
- Drug Abiraterone
Abiraterone 1000 mg administered orally once daily (QD) in combination with prednisone/prednisolone according to local prescribing information.
- Drug Androgen Deprivation Therapy (ADT)
Background therapy consisting of a gonadotropin-releasing hormone (GnRH) agonist/antagonist or prior orchiectomy to maintain castrate testosterone levels (\<50 ng/dL \[\<1.7 nmol/L\]). All participants will continue ADT throughout study participation.
- Drug Darolutamide
Darolutamide 600 mg administered orally twice daily (BID).
- Drug Prednisone/Prednisolone
Oral corticosteroid administered with abiraterone in Phase I Group B according to local prescribing information.
- Drug Tulmimetostat
Tulmimetostat is an oral dual EZH1/EZH2 inhibitor administered once daily. In Phase I, escalating dose levels will be evaluated in combination with darolutamide or abiraterone. In Phase II, one or two dose levels selected from Phase I will be evaluated in combination with darolutamide.
Outcome measures
Primary outcome
Phase I (Group A and Group B): Dose-limiting toxicities (DLTs)
A dose-limiting toxicity was defined as an adverse event or abnormal laboratory value that was not clearly attributable to the underlying disease or an extraneous cause, occurred during the first 28 days of treatment with tulmimetostat, and met the protocol-defined dose-limiting toxicity criteria. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Dose-limiting toxicities were included in the Bayesian Logistic Regression Model used to support dose-escalation decisions.
Time frame From the first dose of study treatment through the end of Cycle 1, up to 28 days
Primary outcome
Phase I (Group A and Group B): Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
The incidence, type, frequency, seriousness, and severity of adverse events and serious adverse events will be summarized. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.
Time frame From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
Primary outcome
Phase I (Group A and Group B): Number of Participants with dose adjustments
The number of participants with dose reductions, dose interruptions, or permanent discontinuations, including the reasons for the dose adjustments, will be summarized by treatment group and dose cohort.
Time frame From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
Primary outcome
Phase I (Group A and Group B): Dose Intensity
Dose intensity, calculated as the actual cumulative dose received divided by the actual duration of exposure, and relative dose intensity, calculated as the dose intensity divided by the planned dose intensity, will be summarized using descriptive statistics for each study drug.
Time frame From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
Primary outcome
Phase I (Group A and Group B): Duration of exposure to each study drug
The duration of exposure, in months, to each study drug will be summarized using descriptive statistics by treatment group and dose cohort.
Time frame From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
Primary outcome
Phase II (Group A): Prostate-Specific Antigen (PSA) response rate of < 0.2 ng/mL at Month 6
Prostate-Specific Antigen (PSA) response rate is defined as the proportion of participants who achieved a prostate-specific antigen level below 0.2 ng/mL at Month 6, confirmed by a second prostate-specific antigen assessment performed at least 3 weeks later.
Time frame At Month 6, with confirmation by a second prostate-specific antigen assessment performed at least 3 weeks later
Secondary outcome
Phase I (Group A): Plasma concentrations of Tulmimetostat and Darolutamide
Plasma concentrations of tulmimetostat and darolutamide will be evaluated using pharmacokinetic samples collected from participants across the evaluated dose levels in Phase I, Group A.
Time frame Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Cycle 1, Day 2: 0 and 24 hours post-dose for tulmimetostat; Cycle 1, Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days
Secondary outcome
Phase I (Group A): AUC of Tulmimetostat and Darolutamide
The area under the concentration-time curve from time zero to the last quantifiable concentration, the area under the concentration-time curve from time zero extrapolated to infinity, and the area under the concentration-time curve over a dosing interval at steady state will be derived, as applicable, and summarized using descriptive statistics.
Time frame Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Cycle 1, Day 2: 0 and 24 hours post-dose for tulmimetostat; Cycle 1, Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days
Secondary outcome
Phase I (Group A): Maximum Observed Plasma Concentration (Cmax) of Tulmimetostat and Darolutamide
The maximum observed plasma concentration of tulmimetostat and darolutamide will be derived, as applicable, and summarized using descriptive statistics.
Time frame Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Cycle 1, Day 2: 0 and 24 hours post-dose for tulmimetostat; Cycle 1, Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days
Secondary outcome
Phase I (Group B): Plasma concentrations of Tulmimetostat and Abiraterone
Plasma concentrations of tulmimetostat and abiraterone will be evaluated using pharmacokinetic samples collected from participants across the evaluated dose levels in Phase I, Group B.
Time frame Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Day 2: 0 and 24 hours post-dose; Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days.
Secondary outcome
Phase I (Group B): AUC of Tulmimetostat and Abiraterone
The area under the concentration-time curve from time zero to the last quantifiable concentration, the area under the concentration-time curve from time zero extrapolated to infinity, and the area under the concentration-time curve over a dosing interval at steady state will be derived, as applicable, and summarized using descriptive statistics.
Time frame Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Day 2: 0 and 24 hours post-dose; Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days.
Secondary outcome
Phase I (Group B): Maximum Observed Plasma Concentration (Cmax) of Tulmimetostat and Abiraterone
The maximum observed plasma concentration of tulmimetostat and abiraterone will be derived, as applicable, and summarized using descriptive statistics.
Time frame Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Day 2: 0 and 24 hours post-dose; Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days.
Secondary outcome
Phase II (Group A): Radiographic progression free survival (rPFS)
Radiographic progression free survival (rPFS) is defined as the time from randomization to the first documented disease progression according to Prostate Cancer Working Group 3-modified Response Evaluation Criteria in Solid Tumors, version 1.1, as assessed by the investigator, or death from any cause, whichever occurred first.
Time frame From randomization until the first documented radiographic disease progression or death from any cause, whichever occurs first, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A):Overall survival (OS)
Overall survival (OS) is defined as the time from randomization to death from any cause.
Time frame From randomization until death from any cause, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Objective Response Rate (ORR)
Objective response (OR) is defined as the proportion of participants with a best overall response of confirmed complete response or partial response according to Prostate Cancer Working Group 3-modified Response Evaluation Criteria in Solid Tumors, version 1.1, as assessed by the investigator.
Time frame From randomization until disease progression, death, or the last adequate tumor assessment, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Best Overall Response (BOR)
Best Overall response (BOR) is defined as the best response recorded from the start of study treatment until disease progression or recurrence according to Prostate Cancer Working Group 3-modified Response Evaluation Criteria in Solid Tumors, version 1.1, as assessed by the investigator.
Time frame From randomization until disease progression or death from any cause, whichever occurred first, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Duration of Response (DOR)
Duration of response (DOR) is defined, for participants with a confirmed complete or partial response, as the time from the first documented response until the first documented disease progression according to Prostate Cancer Working Group 3-modified Response Evaluation Criteria in Solid Tumors, version 1.1, as assessed by the investigator, or death from any cause.
Time frame From the first documented complete or partial response until disease progression or death from any cause, whichever occurred first, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Prostate-Specific Antigen 50 (PSA50) response rate
Prostate-Specific Antigen 50 (PSA50) response is defined as a reduction of at least 50% from baseline in prostate-specific antigen at any post-baseline time point, confirmed by a second prostate-specific antigen assessment performed at least 3 weeks later.
Time frame From randomization until the last prostate-specific antigen assessment, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Prostate-Specific Antigen (PSA) Response below 0.1 ng/mL
Prostate-Specific Antigen (PSA) Response below 0.1 ng/mL is defined as achievement of a prostate-specific antigen level below 0.1 ng/mL at any post-baseline time point.
Time frame From randomization until the last prostate-specific antigen assessment, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Time to castration-resistant prostate cancer (CRPC)
Time to castration-resistant prostate cancer was defined as the time from randomization to the first occurrence of prostate-specific antigen progression, radiographic progression based on bone lesions, or radiographic progression based on soft-tissue or visceral lesions.
Time frame From randomization until prostate-specific antigen progression, radiographic progression in bone, or radiographic progression in soft-tissue or visceral lesions, whichever occurred first, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
The analysis of adverse events will include categorization by type, frequency, and severity, as graded by the NCI CTCAE version 5.0.The incidence, type, frequency, seriousness, and severity of adverse events and serious adverse events will be summarized by treatment arm. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.
Time frame From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Number of Participants with dose adjustments
The number of participants with dose reductions, dose interruptions, or permanent discontinuations, including the reasons for the dose adjustments, will be summarized by treatment arm.
Time frame From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Dose Intensity
Dose intensity, calculated as the actual cumulative dose received divided by the actual duration of exposure, and relative dose intensity, calculated as dose intensity divided by planned dose intensity, will be summarized using descriptive statistics for each study drug and treatment arm.
Time frame From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Duration of exposure to each study drug
The duration of exposure, in months, to each study drug will be summarized using descriptive statistics by treatment arm.
Time frame From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
Secondary outcome
Phase II (Group A): Plasma concentrations of tulmimetostat and darolutamide in participants included in intensive pharmacokinetic sampling
Plasma concentrations of tulmimetostat and darolutamide will be evaluated in selected participants receiving tulmimetostat in combination with darolutamide.
Time frame Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Cycle 1, Day 2: 0 and 24 hours post-dose for tulmimetostat; Cycle 1, Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days
Secondary outcome
Phase II (Group A): Plasma concentrations of Tulmimetostat
Plasma concentrations of tulmimetostat will be evaluated using pharmacokinetic samples collected from participants receiving tulmimetostat across the evaluated Phase II dose levels.
Time frame Cycles 1 and 2, Day 1: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days
Secondary outcome
Phase II (Group A): Time to first symptomatic skeletal event (TTSSE)
Time to first symptomatic skeletal event (TTSSE) is defined as the time from the first dose of study treatment to the first occurrence of a new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgery, radiation therapy to relieve bone pain, or death from any cause, whichever occurred first, as assessed by the investigator.
Time frame From the first dose of study treatment until the first symptomatic skeletal event, assessed up to approximately 79 months
Dates
| Start date | January 13, 2026 (actual) |
|---|---|
| Primary completion | August 2, 2032 (estimated) |
| Completion | August 2, 2032 (estimated) |
| First posted | September 24, 2025 (actual) |
| Last updated | November 13, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | November 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
29 sites are recruiting
Australia
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Camperdown | New South Wales | Withdrawn |
| Novartis Investigative Site | Wollongong | New South Wales | Recruiting |
Brazil
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Porto Alegre | Rio Grande do Sul | Recruiting |
Canada
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Montreal | Quebec | Recruiting |
China
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Guangzhou | Recruiting |
France
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Créteil | Recruiting | |
| Novartis Investigative Site | Lille | Recruiting | |
| Novartis Investigative Site | Nantes | Recruiting |
Germany
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Essen | Recruiting | |
| Novartis Investigative Site | Jena | Thuringia | Recruiting |
Hong Kong
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Hong Kong | Recruiting |
Hungary
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Budapest | Recruiting | |
| Novartis Investigative Site | Budapest | Recruiting | |
| Novartis Investigative Site | Szeged | Recruiting |
Italy
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Rozzano | MI | Recruiting |
| Novartis Investigative Site | Verona | VR | Active, not recruiting |
South Korea
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Seoul | Recruiting | |
| Novartis Investigative Site | Seoul | Recruiting |
Spain
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Madrid | Recruiting | |
| Novartis Investigative Site | Madrid | Recruiting | |
| Novartis Investigative Site | Madrid | Recruiting |
Turkey (Türkiye)
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Ankara | Sihhiye Altindag | Recruiting |
United Kingdom
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | London | Recruiting |
United States
| Facility | City | State or region | Status |
|---|---|---|---|
| Univ of Alabama at Birmingham | Birmingham | Alabama | Recruiting |
| Medical University of South Carolina MUSC | Charleston | South Carolina | Recruiting |
| Duke University Medical Center | Durham | North Carolina | Recruiting |
| Uni Of Iowa Hospitals And Clinics | Iowa City | Iowa | Recruiting |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | Recruiting |
| Huntsman Cancer Institute | Salt Lake City | Utah | Recruiting |
| University of Kansas Cancer Center | Westwood | Kansas | Recruiting |
| Wichita Urology Group PA | Wichita | Kansas | Recruiting |
Study documents
No documents are linked in this registry record.
Changes over time
No changes have been recorded since we first ingested this record.
A change is recorded each time the sponsor updates the registry record. Status, dates, enrolment and sites appear here as they move.